Incyte's Undervalued as Pipeline Progresses
February 18, 2019 at 07:00 AM EST
A broad array of oncology and autoimmune programs gives the company a larger margin of error.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|